Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety and Tolerability of Epcoritamab with Drug Combination for Patients with B-cell Non-Hodgkin Lymphoma

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a type of cancer called Non-Hodgkin Lymphoma, specifically a subtype known as B-cell Non-Hodgkin's lymphoma. The study is testing a treatment called Epcoritamab, which is a type of medicine known as a bispecific antibody. This treatment will be used in combination with other cancer-fighting drugs, also known as anti-neoplastic agents. The main goal of the study is to understand how safe and tolerable Epcoritamab is when used with these other drugs.

Participants in the study will receive Epcoritamab along with other medications, which may include Revlimid (containing lenalidomide), Decortin (containing prednisolone), Cyclophosphamide, Truxima (containing rituximab), IMBRUVICA (containing ibrutinib), Venetoclax (also known as ABT-199), Adriblastin (containing doxorubicin hydrochloride), Polivy (containing polatuzumab vedotin), and Golcadomide (also known as BMS-986369/CC-99282). Some participants may receive a placebo instead of one of these medications. The study will help determine the best dose of Epcoritamab to use in future research.

The study will take place over several years, with participants receiving treatment and being monitored for any side effects or changes in their condition. The researchers will look at how the cancer responds to the treatment, how long any positive effects last, and how long it takes for the cancer to progress or for participants to need another type of treatment. This information will help doctors understand how effective Epcoritamab is when used with other cancer treatments for people with B-cell Non-Hodgkin's lymphoma.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes a review of medical history and a physical examination.

    Diagnostic tests such as PET/CT scans are performed to identify measurable disease sites.

  2. Step 2

    Treatment phase 1

    The first phase of treatment involves the administration of epcoritamab in combination with other medications.

    Medications include lenalidomide (Revlimid) taken orally in capsule form, prednisolone (Decortin) in tablet form, and cyclophosphamide administered intravenously.

    The frequency and dosage of these medications are determined by the study protocol and adjusted based on individual response and tolerance.

  3. Step 3

    Treatment phase 2

    In the second phase, additional medications such as rituximab (Truxima) and ibrutinib (IMBRUVICA) are introduced.

    Rituximab is given as an infusion, while ibrutinib is taken orally in capsule form.

    The treatment continues with regular monitoring to assess safety and effectiveness.

  4. Step 4

    Treatment phase 3

    The third phase includes the administration of venetoclax and epcoritamab.

    Venetoclax is taken orally as a film-coated tablet, and epcoritamab is given as a subcutaneous injection.

    The treatment regimen is adjusted based on the patient's response and any side effects experienced.

  5. Step 5

    Treatment phase 4

    In the final phase, additional medications such as doxorubicin hydrochloride (Adriblastin) and polatuzumab vedotin (Polivy) are administered.

    Doxorubicin is given intravenously, while polatuzumab is provided as an infusion.

    The treatment aims to maximize therapeutic benefits while minimizing adverse effects.

  6. Step 6

    Follow-up and monitoring

    After completing the treatment phases, regular follow-up visits are scheduled to monitor health status and response to treatment.

    These visits may include physical examinations, imaging tests, and laboratory assessments to evaluate the effectiveness and safety of the treatment.

Who can join the trial?

5 criteria

  • Must be an adult, male or female, at least 18 years old.
  • Must have a diagnosis of **Diffuse Large B-Cell Lymphoma (DLBCL)**, which is a type of cancer that affects the lymphatic system. This can be a new diagnosis or a transformation from other types of lymphoma.
  • The disease must be confirmed as **CD20+**, which means the cancer cells have a specific protein on their surface.
  • Must have an **ECOG performance status** of 0 to 2. This is a scale that measures how well a person can perform daily activities, with 0 being fully active and 2 being able to do some activities but not work.
  • Must have at least one measurable site of disease. This means there should be a tumor that can be seen and measured using imaging tests like a **PET/CT scan**. The tumor should be at least 1.5 cm in size if it's in a lymph node, or at least 1.0 cm if it's outside a lymph node.

Who cannot join the trial?

7 criteria

  • Patients who have a different type of cancer than B-cell Non-Hodgkin's lymphoma or diffuse large B-cell lymphoma cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are not able to safely receive the study treatment due to other health conditions cannot participate.
  • Patients who are pregnant or breastfeeding cannot participate.
  • Patients who have participated in another clinical trial recently may not be eligible.
  • Patients who have certain infections or diseases that could interfere with the study cannot participate.
  • Patients who are unable to follow the study procedures or attend required visits cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Epcoritamab is a medication being studied for its safety and how well it is tolerated when used with other cancer-fighting drugs in people with a type of cancer called Non-Hodgkin Lymphoma. The goal is to find out how safe it is and to determine the best dose to use in future studies.

What is already known about the treatment

Epcoritamab – Epcoritamab is administered as a subcutaneous injection, meaning it is injected under the skin. It is currently being studied in clinical trials, particularly in combination with other cancer-fighting drugs, to assess its safety and effectiveness. The main therapeutic use of Epcoritamab is for treating B-cell Non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. At the molecular level, Epcoritamab works by engaging the immune system to target and destroy cancer cells. It is classified as a bispecific antibody, which means it can bind to two different types of antigens, helping the immune system recognize and attack cancer cells more effectively.

Investigated diseases

  • B-cell Non-Hodgkin's Lymphoma

    This is a type of cancer that originates in the lymphatic system, specifically affecting B-lymphocytes, which are a type of white blood cell. It is characterized by the uncontrolled growth of these cells, which can form tumors in lymph nodes and other parts of the body. The disease can vary in its progression, with some forms being slow-growing and others more aggressive. Symptoms may include swollen lymph nodes, fever, night sweats, and weight loss. The exact cause of B-cell Non-Hodgkin's Lymphoma is not well understood, but it involves genetic mutations in the B-cells.

  • Diffuse Large B-cell Lymphoma

    This is a specific subtype of B-cell Non-Hodgkin's Lymphoma and is considered the most common form of this disease. It is characterized by rapidly growing tumors in the lymph nodes, spleen, liver, or other organs. The disease progresses quickly and requires prompt medical attention. Symptoms often include swelling of lymph nodes, fever, night sweats, and unexplained weight loss. The cause of Diffuse Large B-cell Lymphoma is not fully known, but it involves genetic changes in the B-cells.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2023-505347-38-00Protocol codeM22-132Estimated enrolment133 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.